MetricSide LogoMetricSide
Learn
  1. Home
  2. Companies
  3. Healthcare
  4. CLOV
OverviewMetricsPricesRevenue & ProfitAssets & LiabilitiesCash FlowMarginsPrice RatiosOthers
MetricSide

Standardized stock fundamentals and valuation metrics. Analyze revenue, EBITDA, free cash flow, and more with interactive charts.

Stock Sectors

  • Technology
  • Healthcare
  • Financials
  • Consumer
  • Industrials
  • Energy
  • Real Estate
  • Materials

Legal & Contact

  • Terms of Service
  • Privacy Policy
  • Contact Us
Not Financial Advice: MetricSide is a data aggregation and visualization tool. Nothing on this website constitutes investment advice, a recommendation, or a solicitation to buy or sell any security. All data is provided for informational and educational purposes only. Past performance is not indicative of future results. Always consult a qualified financial professional before making investment decisions. Data accuracy is not guaranteed — verify critical information against official sources.

© 2026 MetricSide. All rights reserved.

Clover Health Investments (CLOV) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Clover Health Investments
NasdaqGS•Healthcare•Healthcare Plans
$4.56-0.10(-0.02%)Pre-market
Market Cap
$2.39B
P/S
1.0x
P/B
6.4x

Clover Health Investments, Corp. provides medicare advantage plans in the United States. The company offers preferred provider organization and health maintenance organization plans to medicare-eligible individuals. It also operates Clover Assistant, a software platform for physicians to detect, identify, and manage chronic diseases. The company was founded in 2014 and is based in Wilmington, Delaware.

B

How this company scores

GoodMetricSide Score: 65/100

Strongest: Cash & Earnings Quality (20/25); weakest: Profitability (12/25).

Profitability12/25
Growth18/25
Balance Sheet & Red Flags15/25
Cash & Earnings Quality20/25
Strengths
Growing revenueLong cash runwayInterest easily coveredCash-backed earnings

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/S · 1.0x5y range 0.1x – 2.9x
P/S 1.0x · above its 20-quarter median

Currently above its 20-quarter median.

P/B · 6.4x5y range 1.2x – 7.5x
P/B 6.4x · above its 20-quarter median

Currently above its 20-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Watch

FCF/Net Income has dropped below 0.7x in 3 quarters — monitor for earnings quality deterioration.

Price & Volume
Market Cap $2.39B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue
$2.48B
6Q
Q. Revenue
$743.17M
56%
TTM EBITDA
$-16.46M
2Q
TTM Op. Income
$-18.36M
2Q
Q. Op. Income
$28.00M
2Q
TTM Net Income
$-18.36M
2Q
Q. Net Income
$28.00M
2Q
EPS
$0.05
Shares Out.
$524.19M
3%
$2.48B in TTM revenue grew 54.0% YoY, reaching $743.17M last quarter. TTM EBITDA of $-16.46M and TTM operating income of $-18.36M show growth is flowing through to the bottom line. However, net income is negative at $18.36M — growth is not yet reaching the bottom line. Across the last 8 quarters, TTM revenue has risen for 6 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin
3.8%
2Q
Op. Margin
3.8%
2Q
Net Margin
3.8%
2Q
Op. margin of 3.8% is up 6.0% YoY — cost efficiency is improving. Net margin at 3.8% Across the last 8 quarters, operating margin has risen for 2 consecutive quarters — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio
N/A
P/S Ratio
1.0x
9%
P/B Ratio
6.4x
54%
P/S of 1.0x and P/B of 6.4x. P/S is low relative to typical market levels.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets
$720.33M
2Q
Cash
$198.84M
2Q
Long-Term Debt
N/A
Book Value
$376.26M
2Q
D/E Ratio
N/A
Debt/EBITDA
0.0

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow
$25.19M
366%
TTM Free Cash Flow
$74.21M
2Q
FCF Margin
3.0%
2Q
FCF / Net Income
-4.0
3Q
TTM FCF of $74.21M on $25.19M in operating cash flow. The FCF / Net Income ratio of -4.0x means the business consumes cash — it is not yet self-funding. Across the last 8 quarters, free cash flow has risen for 2 consecutive quarters — an improving trend.

Related Stocks in Healthcare

View Sector
LLY$938.28B
Lilly (Eli)
Drug Manufacturers - General
JNJ$586.47B
Johnson & Johnson
Drug Manufacturers - General
ABBV$411.57B
AbbVie
Drug Manufacturers - General
MRK$303.29B
Merck & Co.
Drug Manufacturers - General
UNH$249.74B
UnitedHealth Group
Healthcare Plans
TMO$203.77B
Thermo Fisher Scientific
Diagnostics & Research
AMGN$201.34B
Amgen
Drug Manufacturers - General
GILD$191.61B
Gilead Sciences
Drug Manufacturers - General

Cash Burn

Watch

FCF turned negative in 3 of the last 8 quarters — occasional cash consumption.

Share Dilution

Red Flag

Shares outstanding increased 6.9% — significant dilution, likely from stock compensation or capital raises.